Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan.
Jpn J Clin Oncol. 2011 Aug;41(8):1013-6. doi: 10.1093/jjco/hyr089. Epub 2011 Jul 7.
Thymic carcinoma is a rare cancer of the thymus, different from thymoma in respect of its malignant nature, and no standard chemotherapy for this cancer has been established yet.
We conducted a retrospective review of the efficacy of combination chemotherapy with carboplatin (an area under the curve of 6) and paclitaxel (200 mg/m(2)) in 16 patients with histologically or cytologically proven thymic carcinoma, Masaoka Stage IVa/IVb or post-operative recurrent disease.
There were 13 males and 3 females, with a median (range) age of 56 (38-73) years. Squamous cell carcinoma was the most common (n= 12), followed by undifferentiated carcinoma (n= 2) and others (n= 2). Four, nine and three patients had Stage IVa, IVb and post-operative recurrent disease, respectively. Two and four patients showed complete and partial responses, respectively, representing a response rate (95% confidence interval) of 37.5 (15.2-64.6)%. The median (95% confidence interval) progression-free and overall survivals in the 16 patients were 8.6 (1.8-15.3) and 49.4 (30.1-68.8) months, respectively.
Combination therapy with carboplatin and paclitaxel yielded an objective response in about one-third of the patients with advanced thymic carcinoma.
胸腺癌是一种罕见的胸腺恶性肿瘤，与胸腺瘤在恶性程度上有所不同，目前尚未建立针对这种癌症的标准化疗方案。
我们回顾性分析了 16 例经组织学或细胞学证实的胸腺癌（Masaoka 分期 IVa/IVb 期或术后复发）患者接受顺铂（曲线下面积 6）联合紫杉醇（200mg/m²）联合化疗的疗效。
16 例患者中，男性 13 例，女性 3 例，中位（范围）年龄 56（38-73）岁。最常见的组织学类型为鳞状细胞癌（n=12），其次为未分化癌（n=2）和其他类型（n=2）。4 例、9 例和 3 例患者分别为 Masaoka IVa 期、IVb 期和术后复发。2 例和 4 例患者分别达到完全缓解和部分缓解，缓解率（95%可信区间）为 37.5%（15.2-64.6）。16 例患者的中位（95%可信区间）无进展生存期和总生存期分别为 8.6（1.8-15.3）个月和 49.4（30.1-68.8）个月。
顺铂联合紫杉醇的联合化疗方案使约三分之一的晚期胸腺癌患者获得了客观缓解。
